---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003514"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:01:33.565239+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Renalytix publishes real-world data showing KidneyIntelX slows CKD progression and improves diabetes control

## Summary
- Study of 2,569 patients with Type 2 diabetes and DKD: KidneyIntelX deployment associated with slowed kidney function decline and improved A1C levels.
- 61% increase in preventative drug prescriptions among high-risk group; improved specialist referrals.
- KidneyIntelX has Medicare, Medicaid, and Blue Cross coverage; FDA de novo authorization received June 2023.
- 27% of study cohort were Black patients; median age 68, BMI 30, 89% hypertension.

## SEC filing metadata
- accession: 0000950170-24-003514
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024003514/0000950170-24-003514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024003514/rnlx-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003514
- JSON: https://secwatch.observer/filing/0000950170-24-003514.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.